PFPG
BMRN icon

Pinnacle Financial Partners (Georgia)’s BioMarin Pharmaceuticals BMRN Stock Holding History

Pinnacle Financial Partners (Georgia)’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.01M Buy
35,081
+172
+0.5% +$9.42K 0.01% 492
2026
Q1 		$1.97M Buy
+34,909
New +$2.04M 0.02% 457

Other funds holding BMRN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Pinnacle Financial Partners (Georgia)'s BMRN Position: Q2 2026 in Review

Pinnacle Financial Partners (Georgia) increased its BioMarin Pharmaceuticals (BMRN) stake by 0.49% in Q2 2026, buying an estimated $9.42K and bringing the position to 35,081 shares worth $2.01M. The position accounts for 0.01% of the portfolio, ranked #492.

Pinnacle Financial Partners (Georgia) first reported a position in BMRN in Q1 2026 and has held it in 2 quarters since. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

  • Pinnacle Financial Partners (Georgia) held 35,081 shares of BioMarin Pharmaceuticals worth $2.01M as of Q2 2026.
  • Pinnacle Financial Partners (Georgia) bought 172 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $9.42K.
  • BioMarin Pharmaceuticals made up 0.01% of Pinnacle Financial Partners (Georgia)'s portfolio in Q2 2026, its #492 holding.
  • Pinnacle Financial Partners (Georgia) first reported a position in BioMarin Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Pinnacle Financial Partners (Georgia)'s 13F filing for Q2 2026, filed 14 Aug 2026.